Home › Therapeutic areas › Oncology › Renal Cell Carcinoma

Renal Cell Carcinoma (10 companies)

Companies with an active program in Renal Cell Carcinoma.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ALLO Allogene Therapeutics ImmunologyOncology Rare 1 Phase 2 $256M 10
RCUS Arcus Biosciences DermatologyImmunology+1 2 Phase 3 $2.36B 8
CMPX Compass Therapeutics Oncology 1 Phase 2 $109M 15
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 1 Phase 3 $858M 7
EXEL Exelixis CardiovascularOncology 3 Approved $16.7B 23
KURA Kura Oncology MetabolicOncology 1 Approved $688M 13
NVCT Nuvectis Pharma HematologyOncology+1 Rare 1 Phase 3 $660M 9
SMMT Summit Therapeutics Oncology 1 NDA Submitted $8.53B 6
TLX Telix Pharmaceuticals Oncology 3 Approved $3.01B 25
XNCR Xencor ImmunologyNeurology+1 Rare 3 Approved $2.59B 28